BBOT Officer Mehra Uneek Files Form 3 Showing No Beneficial Ownership

Rhea-AI Filing Summary

Mehra Uneek, serving as Chief Financial Officer and a director of BridgeBio Oncology Therapeutics, Inc. (BBOT), filed an initial Form 3 reporting the event date 08/11/2025. The filing states no securities are beneficially owned by the reporting person and attaches an Exhibit 24 power of attorney. The form was signed by an attorney-in-fact on 08/18/2025.

Positive

• Compliance with Section 16 via timely initial Form 3 filing
• No beneficial ownership reported reduces immediate insider-trading disclosure concerns

Negative

• None.

Insights

Corporate Governance Analyst

Initial disclosure shows no beneficial ownership by an executive director.

The filing documents that the reporting person holds the titles of Chief Financial Officer and director and that no securities are beneficially owned as of the reported event date 08/11/2025. This is an initial Section 16 filing required when an officer or director assumes a reporting position.

Key dependencies include timely updates if holdings change; investors can expect subsequent Forms (4 or 5) if any securities are acquired or disposed. The signature by an attorney-in-fact on 08/18/2025 completes the filing process.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 08/18/2025 - 05:08 PM Learn about SEC filing dates

FAQ

What did Mehra Uneek disclose on the Form 3 for BBOT?

Mehra Uneek disclosed holding the positions of Chief Financial Officer and director and reported no securities beneficially owned as of 08/11/2025.

Does the Form 3 for BBOT show any stock or option holdings?

No. The filing explicitly states no securities are beneficially owned by the reporting person.

When was the Form 3 for Mehra Uneek signed?

The Form 3 was signed by an attorney-in-fact on 08/18/2025.

What happens if the reporting person acquires securities after this Form 3?

Any future acquisitions or dispositions would require a subsequent Form 4 (or Form 5 if eligible) to report the transactions within the statutory timelines.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Mehra Uneek

(Last) (First) (Middle)

BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.

256 EAST GRAND AVENUE, SUITE 104

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
08/11/2025

3. Issuer Name and Ticker or Trading Symbol
BridgeBio Oncology Therapeutics, Inc. [ BBOT ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Aaron Chan, Attorney-in-Fact	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.